Form 4: Nektar Therapeutics CEO Sells Shares to Cover Tax Obligations

Nektar Therapeutics CEO, Howard W. Robin, sold 16,278 shares of common stock to cover tax obligations related to vesting of restricted stock units.

Summary

• Howard W. Robin, the President and CEO of Nektar Therapeutics, sold 16,278 shares of common stock on November 19, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• The shares were sold at a weighted average price of $1.01, with individual trades ranging from $1.00 to $1.04.
• Following the transaction, Robin directly owns 832,080 shares of Nektar Therapeutics common stock and indirectly owns 410 shares through a spouse.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• The sale of 16,278 shares is not unusual for a CEO of a company of Nektar's size.
• The weighted average price of $1.01 is within the expected range for the stock's recent trading history.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on the stock price, but it is not expected to be significant given the reason for the sale.

Key Dates

Keywords

Nektar Therapeutics, Howard W. Robin, stock sale, insider trading, Form 4, tax obligations, RSUs, executive compensation